复宏汉霖(02696)自主研发的HLX37在晚期/转移性实体瘤患者中的1期临床试验申请获NMPA批准

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has received approval from the National Medical Products Administration (NMPA) for its investigational new drug (IND) application for HLX37, a bispecific antibody targeting PD-L1 and VEGF, in patients with advanced/metastatic solid tumors [1] Group 1 - The drug HLX37 is a recombinant humanized bispecific antibody [1] - The approval pertains to a Phase 1 clinical trial for patients with advanced or metastatic solid tumors [1]